research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research IDIOPATHIC HYPOPARATHYROIDISM; A REPORT OF 2 CASES
Idiopathic hypoparathyroidism is rare and can be managed with dihydrotachysterol.
research Transient treatment response of platelet-rich plasma injection for temporal triangular alopecia: A case report with dermoscopic examination follow-up
PRP injections are not effective for long-term treatment of temporal triangular alopecia.
research TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold
Some hair loss drugs can cause a unique type of hair loss that resembles both psoriasis and alopecia.
research Platelet-Rich Plasma Hybridized Adipose Transplant (PHAT) for the Treatment of Hair Loss
research Effect of cyproterone acetate on rate of hair growth in hirsute females
Cyproterone acetate reduced hair growth in most hirsute females and made hair softer, thinner, and lighter.
research Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
Rezpegaldesleukin shows promise for treating severe alopecia areata.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Clin-Alert
In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
research Autotaxin–lysophosphatidic acid– LPA 3 signaling at the embryo‐epithelial boundary controls decidualization pathways
LPA3 signaling in the uterus is crucial for placental formation and fetal development.
research Formulation and optimization of folate-bovine serum albumin-coated ethoniosomes of pterostilbene as a targeted drug delivery system for lung cancer: In vitro and in vivo demonstrations
The new drug delivery system effectively targets lung cancer cells.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research Drug-induced alopecia after dupilumab therapy
Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
research Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies
A new patch can deliver stable antibodies over time for potential HIV treatment.
research SIMULTANEOUS DETERMINATION OF FINASTERIDE AND TAMSULOSIN IN COMBINED DOSAGE FORM BY USING RP-HPLC METHOD
Method accurately measures finasteride and tamsulosin in combined drug form.
research Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
research Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata
Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
research A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
Entadfi, a mix of finasteride and tadalafil, is used for BPH.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Propylthiouracil-induced Alopecia Accompanying Hypohidrosis and Onychomadesis
Propylthiouracil can cause hair loss, reduced sweating, and nail issues, but stopping the drug can reverse hair and nail problems.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.